SEARCH

SEARCH BY CITATION

References

  • Bruno, B., Rotta, M., Patriarca, F., Mordini, N., Allione, B., Carnevale-Schianca, F., Giaccone, L., Sorasio, R., Omede, P., Baldi, I., Bringhen, S., Massaia, M., Aglietta, M., Levis, A., Gallamini, A., Fanin, R., Palumbo, A., Storb, R., Ciccone, G. & Boccadoro, M. (2007) A comparison of allografting with autografting for newly diagnosed myeloma. New England Journal of Medicine, 356, 11101120.
  • Caballero-Velazquez, T., Lopez-Corral, L., Encinas, C., Castilla-Llorente, C., Martino, R., Rosinol, L., Sampol, A., Caballero, D., Serrano, D. & Heras, I. (2013) San Miguel J, Perez-Simon JA. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post)-allogeneic transplantation for high-risk myeloma patients. British Journal of Haematology, 162, 474482.
  • Crawley, C., Iacobelli, S., Bjorkstrand, B., Apperley, J.F., Niederwieser, D. & Gahrton, G. (2007) Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse ratescompared with myeloablative conditioning. Blood, 109, 35883594.
  • Danylesko, I., Beider, K. & Shimoni, A. (2012) Nagler. Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. Clinical & Developmental Immunology, 2012, 753407.
  • Havelange, V., Antoine-Poirel, H., Saussoy, P., Van Den Neste, E. & Ferrant, A. (2006) Donor cell leukemia developing after haematopoietic stem cell transplantation for multiple myeloma. Acta Clinica Belgica, 61, 8286.
  • Kneppers, E., Van der Holt, B., Kersten, M.J., Zweegman, S., Meijer, E., Huls, G., Cornelissen, J.J., Janssen, J.J., Huisman, C., Cornelisee, P.B., Bruijnen, C.P., Emmelot, M., Sonneveld, P., Lokhorst, H.M., Mutis, T. & Minnema, M.C. (2011) Lenalidomide maintenance after myeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood, 118, 24132419.
  • Koreth, J., Alyea, E.P., Murphy, W.J. & Welniak, L.A. (2009) Proteasome inhibition and allogeneic haematopoietic stem cell transplantation: a review. Biology of Blood and Marrow Transplantation, 15, 15021512.
  • Sahebi, F., Shen, Y., Somlo, G., Thomas, S.H., Htut, M., Karanes, C., Krishnan, A.Y., Murata-Collins, J., Palmer, J., Rincon, A. & Forman, S.J. (2013) Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up study. British Journal of Haematology., 160, 199206.
  • Wolschke, C., Stübig, T., Hegenbart, U., Schönland, S., Heinzelmann, M., Hildebrandt, Y., Ayuk, F., Atanackovic, D., Dreger, P., Zander, A. & Kröger, N. (2013) Post-allograft lenalidomide induces strong NK cell-mediated anti-myeloma activity and risk for T-cell mediated GvHD. Results from a phase I/II Dose-finding study. Experimental Hematology, 41, 134142.